EMA recommends revoking marketing authorisation for Amgen's rare disease drug
26/06/2026 11:53
EMA recommends revoking marketing authorisation for Amgen's rare disease drug June 26 (Reuters) - The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's AMGN.O rare disease drug Tavneos.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Biswas)
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally